Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05118490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Study acronym: 1 to 3
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 28, 2024 to Jul 11, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    • Site details revised at 4 of 4 sites
    v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2023 to Jul 19, 2023
    • Study sites: 1 to 4
    v5
  3. Start date: Oct 30, 2022 to Apr 1, 2023v4
  4. Eligibility criteria expanded, about 189 wordsv3
  5. Study sites: 0 to 1v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.
Trial Details
NCT Number NCT05118490
Lead Sponsor The Aurum Institute NPC
Collaborators: Johns Hopkins University
Conditions
(from sponsor)		 HIV Seropositivity, Tuberculosis, Household Contact
Related terms HIV Seropositivity, Tuberculosis
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov